

November 5, 2013

Lian-Sheng Ma,

President and Company Editor-in-Chief
WJH

Dear Editor,

We are pleased to submit for your consideration an original review article regarding Management of HCV infection in patients with hemodialysis. The invitation ID is 01524125

Prevalence of HCV infection in patients with maintenance hemodialysis (MHD) is relatively higher than those without MHD. Chronic HCV infection detrimentally affects the life quality and expectancy, leads to the rejection of renal transplantation, and increases the mortality of MHD patients. With the application of erythropoietin to improve uremic anemia and avoid blood transfusion, the new HCV infections during MHD in recent years are mainly caused by the shortness of stringent universal precautions. Strict implementation of universal precautions for HCV-transmission have led to markedly decreased HCV infection in many hemodialysis units. The anti-HCV negative HCV infection and the occult HCV infection in MHD patients should be alerted. Standard interferon alpha (ST-IFN α) and pegylated IFN α (PEG-IFN α) monotherapy with reduced dose are currently the main treatment strategies for MHD patients with active HCV replication, but how to increase the sustained virological response (SVR) and decrease the side-effects are key problems. IFN α -free treatments with two or three direct-acting antivirals (DAAs) without ribavirin (RBV) in MHD patients are waiting for the future investigation.

We are busy in preparing this review, so we had not sent out for English checking, we believe 95% of the English is perfect, and we are planning to perform English check after WJG provided the reviewer's comments. So I hope you may understand me.

This manuscript has not been submitted for review or accepted elsewhere. We have no potential conflicts of interest in this study, and all authors have contributed to, seen, and approved the final submitted version of the manuscript. I sincerely hope that the manuscript is in order, and I would greatly appreciate your kind consideration of it for publication in your journal.

Respectfully,

Yue Wang, MD

National Institute for Viral Disease Control and Prevention, China CDC, Beijing 100052,

China; Email: euy-tokyo@umin.ac.jp

Telephone: +86-10-63555751